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Abstract
Background: Passive immunization with antibodies directed to Ab decreases brain Ab/amyloid burden and
preserves memory in transgenic mouse models of Alzheimer’s disease (AD). This therapeutic strategy is under
intense scrutiny in clinical studies, but its application is limited by neuroinflammatory side effects (autoimmune
encephalitis and vasogenic edema).
Methods: We intravenously administered the monoclonal Ab protofibril antibody PFA1 to aged (22 month) male
and female 3 × tg AD mice with intermediate or advanced AD-like neuropathologies, respectively, and measured
brain and serum Ab and CNS cytokine levels. We also examined 17 month old 3 × tg AD female mice with
intermediate pathology to determine the effect of amyloid burden on responses to passive immunization.
Results: The 22 month old male mice immunized with PFA1 had decreased brain Ab, increased serum Ab, and no
change in CNS cytokine levels. In contrast, 22 month old immunized female mice revealed no change in brain Ab,
decreased serum Ab, and increased CNS cytokine levels. Identical experiments in younger (17 month old) female 3
× tg AD mice with intermediate AD-like neuropathologies revealed a trend towards decreased brain Ab and
increased serum Ab accompanied by a decrease in CNS MCP-1.
Conclusions: These data suggest that passive immunization with PFA1 in 3 × tg AD mice with intermediate
disease burden, regardless of sex, is effective in mediating potentially therapeutic effects such as lowering brain Ab.
In contrast, passive immunization of mice with a more advanced amyloid burden may result in potentially adverse
effects (encephalitis and vasogenic edema) mediated by certain proinflammatory cytokines.
Background
A defining pathological hallmark of Alzheimer’s disease
(AD) is the accumulation of Ab/amyloid deposits in brain.
The generation and clearance of Ab, produced from amy-
loid precursor protein (APP) by b- and g-secretases,
remain key therapeutic targets for transgenic AD mouse
models and for clinical studies [1]. Ab naturally exists as
a monomer or as aggregates including oligomers,
protofibrils, and fibrils. Of the two most commonly gener-
ated isoforms of Ab, Ab40 and Ab42, the latter aggregates
more readily to form amyloid fibrils [2,3]. Oligomers and
protofibrils, the intermediate stages of Ab fibril formation,
are neurotoxic in culture and in animal models [4-6] and
these aggregates may correlate better with AD severity
than neuritic plaque density [7,8].
Immunotherapy is an effective method of reducing
brain Ab levels and preserving or improving behavioral
outcome measures in transgenic mouse models of AD.
Initial studies utilized an active immunization approach.
Peripheral injections of synthetic human Ab prevented
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amyloid deposition, decreased CNS Ab/amyloid burden,
and ameliorated memory deficits in mice [9-11]. How-
ever, when this therapy was translated to individuals
with AD, the pivotal clinical trial was terminated early
due to the development of excessive neuroinflammation
(autoimmune encephalitis) in 6% of treated individuals
[12]. Passive immunization with antibodies to Ab may
offer a safer, and reversible, alternative by circumventing
T-cell responses associated with neuroinflammation in
active immunization protocols. Passive immunization
studies show similar efficacy in reducing brain Ab/amy-
loid and preserving memory in transgenic mouse models
of AD [13,14], but the passive immunization approach is
also limited by excessive neuroinflammation and vaso-
genic edema in a subset of treated individuals with AD.
Passive immunization may reduce brain Ab by at least
two distinct mechanisms that are not mutually exclusive:
1) microglial phagocytosis of Ab/amyloid with increased
cytokine production, which requires peripherally adminis-
tered antibodies to cross the blood brain barrier [13], and
2) peripheral sequestration of Ab by antibody in the blood
– referred to as the sink hypothesis [14]. The Ab antibody
in the periphery may act as a sink by binding Ab in the
blood and promoting clearance of Ab from the brain to
the periphery, resulting in increased plasma Ab following
treatment. Others suggest, however, that peripherally-
administered antibody also prolongs the half-life of Ab in
blood, and this explains the resultant increase in plasma
levels. To examine these possibilities, it is important to
measure CNS cytokine levels in addition to serum and
brain Ab levels following passive immunization. It is
unknown whether immunotherapy may prove beneficial
with high levels of CNS amyloid burden, or whether treat-
ment may perhaps be limited to a subset of individuals in
earlier disease stages. Alternatively, antibody dosage may
be tailored to amyloid burden in order to minimize the
risk of encephalitis and vasogenic edema. A recent clinical
study reported increased vasogenic edema with higher
antibody dosage and greater disease burden (as found in
ApoE4-positive subjects) [15]. This is the first study to
suggest differential responses to passive immunization per-
haps due to CNS amyloid burden in a transgenic mouse
model of AD.
We examined whether passive immunization of 3 × tg
AD mice with the monoclonal Ab protofibril antibody
PFA1, which is well-characterized but has not yet been
tested as an immunotherapeutic [16,17], was effective in
lowering brain Ab. The use of 3 × tg AD mice (which
express three human mutant transgenes–APP, PS-1, and
Tau–found in familial AD or a familial tauopathy)
allowed us to investigate CNS Ab levels as well as
downstream effects of PFA1 immunization on tau phos-
phorylation. The 3 × tg AD mice are also known to
have sex-specific differences in CNS amyloid burden,
where females develop Ab pathology at an earlier age
and to a much greater extent than males [18]. This
allowed us to investigate the potential roles of sex and
amyloid burden in response to passive immunotherapy.
Passive immunization of intermediate but not more
advanced stage 3 × tg AD mice resulted in decreased
brain Ab and increased serum Ab, supporting the sink
hypothesis. In the older female mice with advanced
pathology we found no change in brain Ab and an
increase in CNS proinflammatory cytokine levels. Col-
lectively, these data suggest that the potential benefits of
passive (and active) immunization may be optimal in
individuals with less pathology, and that treatment of
individuals with more advanced CNS amyloid burden
may engender potentially deleterious neuroinflamma-
tion. Passive (and active) immunization therapies may
require tailoring to Ab/amyloid disease burden, and may
be considered high risk in subpopulations with advanced
disease due to the development of neuroinflammation,
encephalitis, and vasogenic edema. The critical media-
tors of neuroinflammation in response to passive immu-
nization in tg AD mice or in man, however, remain
unclear.
Methods
Animals
We obtained 3 × tg AD mice (breeding pairs) from Dr.
Frank LaFerla (University of California, Irvine) to estab-
lish our colony. These mice were generated by co-
microinjection of mutant APP (K670M/N671L) and tau
(P301L) transgenes under the control of the Thy 1.2
promoter into mutant PS-1 (M146V) knock-in mice
[19]. We used 3 × tg AD mice at 21.6 ± 0.5 months of
age for vehicle (PBS)-treated females (n = 6), PFA1-trea-
ted females (n = 7), vehicle-treated males (n = 5), and
PFA1-treated males (n = 7). We also used 3 × tg AD
mice at 16.8 ± 0.6 months of age for vehicle-treated
females (n = 5) and PFA1-treated females (n = 5). Mice
were sacrificed by cervical dislocation to eliminate
anesthesia-mediated tau phosphorylation [20], and
brains were snap-frozen in dry ice for biochemical ana-
lyses. All animal experiments were approved by the
Institutional Animal Care and Use Committee at Geor-
getown University.
Antibodies and chemicals
The protofibril Ab monoclonal antibody PFA1 was puri-
fied as described [16,17]. The monoclonal antibody
6E10 was purchased from Invitrogen (Carlsbad, CA).
Phospho-tau antibodies AT8 (Ser202/Thr205) and
AT180 (Thr231) were purchased from Pierce Biotech-
nology (Rockford, IL), and Tau46 detecting total tau was
purchased from Sigma-Aldrich (St. Louis, MO). Syn-
thetic Ab40 and Ab42 were purchased from American
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Peptide (Sunnyvale, CA) and a fraction was dissolved to
a concentration of 0.1 μg/μL ddH20 for gel loading for
immunoblots.
Mouse treatments and plasma collection
Purified PFA1 (100 μg IgG/mouse) or vehicle control
(PBS) was intravenously administered into the tail vein
weekly for 4 weeks. Blood was collected from the facial
vein 1 day prior to the first infusion and from the heart
1 week following the last injection – at the time of
sacrifice. EDTA-treated plasma was prepared, aliquoted,
snap frozen, and stored at -80°C for biochemical assays.
Sample preparation and Ab ELISAs
Brains were homogenized in a 10-fold volume of 50 mM
Tris-HCl buffer, pH 7.6, containing 250 mM sucrose
and protease and phosphatase inhibitors. This crude
brain homogenate was used for immunoblot analysis.
Proteins for immunoblot analysis of tau were sepa-
rated on a 4-15% gradient Tris-HCl SDS-PAGE gel and
transferred to a PVDF membrane. Ab samples were
separated on a 10-20% gradient Tris-Tricine gel
(BioRad, Hercules, CA). The membrane was blocked
with 5% non-fat dry milk and probed with the appropri-
ate primary antibody and HRP-coupled anti-mouse IgG
secondary antibody (Jackson ImmunoResearch, West
Grove, PA). Bands were visualized using a chemilumi-
nescence kit (Pierce, Rockford, IL) and densitometrically
quantified (Quantity One, BioRad).
Soluble Ab was extracted in 0.4% diethylamine (DEA)
as previously described [21]. Briefly, crude 10% homoge-
nate was mixed with an equal volume of 0.4% DEA,
sonicated, and ultracentrifuged for 1 hour at 100,000 ×
g. The supernatant was collected and neutralized with
10% 0.5 M Tris base, pH 6.8. The resulting DEA frac-
tion was used for soluble Ab analyses. For analysis of 22
month old mice, total Ab was analyzed from 10% crude
brain homogenate mixed with 70% FA, which was then
sonicated and ultracentrifuged for 1 hour at 100,000 ×
g. The insoluble fraction was calculated as the difference
between total and soluble Ab. For analysis of 17 month
old mice, we undertook a more direct approach for
measurement of insoluble Ab by resuspending the
remaining pellet following DEA fractionation in 70% FA,
sonicating, and ultracentrifuging to yield the insoluble
Ab fraction. Total Ab was calculated as the sum of mea-
sured soluble and insoluble Ab. Sensitive and specific
ELISAs to human Ab1-40 and Ab1-42 were purchased
from IBL Transatlantic (Toronto, Canada) and con-
ducted per the manufacturer’s protocol.
Cytokine ELISAs
Levels of inflammatory cytokines IL1b, TGFb, TNFa,
MCP-1, and IL4 were measured using Multiplex ELISA
assays from Search Light Sample Testing Service
(Pierce). Levels of SDF1 and RANTES were measured
using ELISA kits from R & D Systems (Minneapolis,
MN).
Statistical analyses
Immunoblots for PFA1 characterization were performed
a minimum of three times. Immunoblots for phospho-
tau and total tau quantification were performed a mini-
mum of two times for all samples collected. All statistics
were calculated using GraphPad Prism 5 software, using
student’s t-test with significance determined as p < 0.05.
Descriptive statistics are displayed as mean ± S.E.M.
Correlational analyses were performed on pairs of vari-
ables and the correlation is indicated as an R2 value
within a 95% confidence interval, with p < 0.05.
Results
PFA1 detects Ab monomers and oligomers
The monoclonal PFA1 antibody was designed and char-
acterized to detect various forms of Ab [16]. To deter-
mine which Ab species from AD 3 × tg mice are
detected by PFA1, we performed an immunoblot of
serum proteins and proteins extracted from brain
homogenates of 3 × tg AD mice, with pure synthetic
human Ab40 and Ab42 as positive controls. PFA1 (left
panel) detected monomeric Ab40 and Ab42; however,
PFA1 detected oligomeric forms of Ab42 with apparent
higher affinity than Ab40 (Fig. 1). The major Ab species
recognized by PFA1 in serum and in brain homogenates
was the 56 kDa complex Ab*56, most likely a tetramer
Figure 1 The protofibril monoclonal antibody PFA1 recognizes
multiple Ab species. 5 μL of serum (S) and 10 μg of soluble
protein extract from brains (B) of 22 month old AD 3 × tg mice
were immunoblotted for Ab with antibody PFA1 (left) or 6E10
(right). 1 μM synthetic Ab40 and Ab42 (right lanes) were loaded for
comparison. Membranes were cut at 15 kDa to subject the lower
panels to a longer exposure for detection purposes. PFA1 detected
the 56 kDa oligomeric form of Ab from serum with high affinity,
similar to 6E10.
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of Ab trimers thought to be the leading culprit inducing
memory deficits in an animal model of AD [6]. The
monoclonal antibody 6E10 (right panel) similarly recog-
nized multiple species of Ab – comparable to those
detected by PFA1. Membranes probed with both PFA1
(left) and 6E10 (right) were cut at ~15 kDa so that the
lower panels could be subjected to longer exposures.
These studies demonstrate that the PFA1 antibody
detects both monomeric and oligomeric forms of Ab
derived from 3 × tg AD mice.
Total brain Ab is decreased in immunized 22 month old
male mice
To determine whether passive immunization of aged 3 ×
tg AD mice decreased brain Ab, we administered weekly
intravenous injections of PFA1 (100 μg/mouse/week) to
22 month-old male and female mice for four weeks.
Brain homogenates were analyzed for DEA-soluble and
total (FA extracted) Ab40 and Ab42. Insoluble Ab was
calculated as the difference between total and soluble
Ab. We found no significant differences in soluble, inso-
luble, or total Ab40 and Ab42 in female mice immu-
nized with PFA1 (Fig. 2A & 2B). In contrast, we found a
significant 48% decrease in insoluble Ab42, a significant
47% decrease in total Ab42, and a downward trend in
soluble Ab42 (32%) following treatment of immunized
male mice at the same age (Fig. 2D). We found similar
trends of decreased Ab40, in both the soluble (30%) and
insoluble (16%) fractions from male mice (Fig. 2C). Rela-
tive values between females and males for Ab40 and
Ab42 were as expected, with females showing higher
levels of Ab40 (60-70 pmol/g tissue) compared to males
(15-20 pmol/g tissue) and higher levels of Ab42 (30-40
pmol/g tissue) compared to males (9-14 pmol/g tissue).
These data reveal that passive immunization with PFA1
decreased brain Ab levels in male, but not female,
22 month-old 3 × tg AD mice.
Plasma Ab is increased in immunized 22 month old male
mice
Plasma Ab levels were measured before and after the
4 week treatment paradigm to determine whether PFA1
sequestered Ab in the periphery. There was a significant
44% decrease (p < 0.01) in plasma Ab40 levels in 22
month-old immunized female mice, and no differences
in plasma Ab42 levels following treatment (Fig. 3A and
3B). However, there was a significant 128% increase (p <
0.05) in plasma Ab40 in males after treatment (Fig. 3C).
Male mice also showed a similar increasing but non-sig-
nificant trend (133%) in plasma Ab42 following treat-
ment (Fig. 3D). These data provide evidence for
peripheral Ab sequestration in 22 month-old male mice
through a decrease in brain Ab with a corresponding
increase in plasma Ab.
CNS TNFa and MCP-1 levels are increased in immunized
22 month old female mice, and unchanged in 22 month
old male mice
Passive immunization to Ab/amyloid may activate
microglia since a small fraction of antibody delivered
intravenously may penetrate the blood-brain barrier. To
determine whether passive immunization induced neu-
roinflammatory responses, we examined cytokines and
chemokines in brain homogenates of 22 month old 3 ×
tg AD mice following four weeks of treatment, including
Interleukin-1b (IL-1b), Transforming Growth Factor b
(TGFb), Tumor Necrosis Factor a (TNFa), Monocyte
Chemotactic Protein-1 (MCP-1, now CCL2, Chemokine
(C-C) motif ligand 2), Interleukin-4 (IL-4), stromal cell-
derived factor-1 (SDF1), and Chemokine (C-C) motif
ligand 5 (CCL5, or RANTES). Immunized females
exhibited markedly increased levels of CNS TNFa (by
459%, p < 0.05) and MCP-1 (by 83%, p < 0.05) com-
pared to PBS-treated mice (Fig. 4A). In contrast, immu-
nized male mice showed no significant differences in
cytokine levels compared to PBS-treated mice (Fig. 4B).
These data suggest a significant neuroinflammatory
response to passive immunization in female but not
male mice at 22 months old.
TGFb and SDF1 are negatively correlated with brain Ab,
while TNFa and MCP-1 are positively correlated
Certain proinflammatory cytokines and chemokines are
up-regulated in human AD brain, such as TNFa and
IL1, while others are down-regulated. To determine
whether specific CNS cytokine levels correlated with
brain Ab levels in 22 month-old female or male 3 × tg
AD mice, we performed the following correlation ana-
lyses. As soluble Ab40 or Ab42 increased, TGFb and
SDF1 decreased in females (Fig. 5A & 5B). In addition,
as insoluble and total Ab40 increased, TNFa also
increased in males (data not shown, and Fig. 5C). When
data from female and male mice were combined, we
again found that TNFa and soluble Ab40 and Ab42
were positively correlated, and in addition, MCP-1 and
all species of Ab40 (soluble, insoluble, and total) and
soluble Ab42 were also positively correlated (Fig. 5D-F).
Collectively, these data reveal a consistent positive cor-
relation of brain Ab levels with the proinflammatory
cytokines TNFa and MCP-1, and a negative correlation
of Ab with TGFb and SDF-1.
Immunized males show a decreased trend in phospho-tau
As demonstrated above, PFA1 immunization decreased
Ab levels in male 3 × tg AD mice, which express three
mutant human transgenes - APP, PS-1, and Tau. There-
fore, we determined whether PFA1 immunization also
affects hTau pathology. To test this, we examined phos-
pho-tau and total tau levels in PFA1-treated versus
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PBS-treated mice. We found no difference in phospho-
tau normalized to total tau in immunized female mice
(Fig. 6A). However, we found a decreasing but non-
significant trend (18%) in phospho-tau in immunized
males, suggesting that passive immunization may have a
downstream beneficial effect on phospho-tau (Fig. 6B). In
aggregate, these data reveal that passive immunization of
22 month old 3 × tg AD mice resulted in decreased brain
Ab and increased serum Ab with no change in CNS
inflammatory cytokines in male mice, while in female
mice with greater amyloid burden we found no effect on
either brain or serum Ab, and accompanied increased
CNS proinflammatory cytokine levels.
Immunized 17 month old female mice reveal a
decreasing trend in brain Ab
We wished to determine whether these results were due
either to sex or to amyloid burden, as the female 3 × tg
AD mice have a significantly greater amyloid load com-
pared to male mice of the same age [18]. Therefore, we
Figure 2 Brain Ab1-42 is decreased in 22 month-old PFA1 treated male mice. A. Ab1-40 levels were measured from DEA-extracted (soluble
proteins, left) and FA-extracted (total proteins, right) brain lysates from vehicle (n = 6) or PFA1-treated (n = 7) female mice following 4 weeks of
treatment. Insoluble Ab levels were calculated as the difference between total and soluble Ab. There were no significant differences in soluble,
insoluble, or total Ab1-40 levels between vehicle and PFA1-treated female mice. B. Ab1-42 levels were measured from DEA and FA lysates from
the same female mice treated with vehicle or PFA1. There were no significant differences in Ab1-42 between vehicle and PFA1-treated female
mice. C. Ab1-40 levels were measured from DEA and FA lysates from vehicle (n = 5) or PFA1-treated (n = 7) male mice. There were trends
towards decreased soluble (30%), insoluble (16%) and total (17%) Ab1-40 in PFA1-treated mice. D. Ab1-42 levels were measured from DEA and
FA lysates from vehicle or PFA1-treated male mice following 4 weeks of treatment. PFA1-treated mice exhibited a trend towards decreased
soluble Ab1-42 (32%) and had a significant decrease in insoluble and total Ab1-42 (48%, p < 0.05, and 47%, p < 0.05, respectively).
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conducted identical experiments with a younger - 17
month old - cohort of female mice. We hypothesized
that if the treatment was effective only in male mice due
to milder burden of pathology, then younger female
mice with reduced pathology may exhibit similar
responses. We performed the same 4-week passive
immunization treatment with PFA1 on 17 month-old
female 3 × tg AD mice, and determined brain levels of
soluble and insoluble Ab40 and Ab42, and calculated
total Ab from the sum of soluble and insoluble Ab.
Immunized 17 month old female mice revealed a trend
towards decreased soluble and insoluble Ab40 (25%
soluble, 17% insoluble) and Ab42 (32% soluble, 24%
insoluble) following treatment (Fig. 7A & 7B). These
data suggest that disease-burden, and not sex, may be
the primary factor driving discrepant results we found
in 22 month old male versus female mice.
Plasma Ab is increased in immunized 17 month old
female mice
Next, we determined whether plasma Ab levels were
affected by immunization. We measured plasma Ab
levels from blood collected before and after the 4 week
treatment paradigm. We found that PFA1-immunized
17 month old female mice revealed a significant 34%
increase in Ab42 (p < 0.05), and an increasing trend
(140%) in Ab40, following treatment (Fig. 8A & 8B).
Figure 3 Plasma Ab is decreased in 22 month old PFA1 treated
female mice and increased in 22 month old PFA1 treated male
mice. A. Ab1-40 levels were measured from plasma collected from
vehicle and PFA1 treated female mice before and after 4 weeks of
treatment. There was no significant change in plasma Ab1-40 levels
following treatment in vehicle treated animals. There was a
significant 44% decrease (p < 0.01) in plasma Ab1-40 levels
following PFA1 treatment. B. Ab1-42 levels were measured from
plasma collected from vehicle and PFA1 treated female mice before
and after treatment. There were no significant changes to Ab1-42 in
either the vehicle or PFA1 group following treatment. C. Ab1-40
levels were measured from plasma collected from vehicle and PFA1
treated male mice before and after 4 weeks of treatment. There was
no significant change in plasma Ab1-40 levels following treatment
in vehicle treated male mice. There was a significant 128% increase
(p < 0.05) in Ab1-40 levels following treatment in the PFA1 treated
male mice. D. Ab1-42 levels were measured from plasma collected
from male mice before and after vehicle or PFA1 treatment. There
were no significant changes to Ab1-42 levels following treatment in
either vehicle or PFA1 group.
Figure 4 CNS TNFa and MCP-1 levels are increased in 22 month
old immunized female mice and unchanged in male mice. A.
Levels of inflammatory cytokines IL1b, TGFb, TNFa, MCP-1, IL4, SDF1,
and RANTES were measured from brain homogenates of vehicle or
PFA1 treated female mice. There were no significant differences in
IL1b, TGFb, IL4, SDF1, or RANTES between vehicle and PFA1 treated
groups. There was a significant 459% (p < 0.05) increase in TNFa, and
an 83% increase (p < 0.05) in MCP-1 following PFA1 treatment in
female mice. B. Levels of inflammatory cytokines IL1b, TGFb, TNFa,
MCP-1, IL4, SDF1, and RANTES were measured from brain
homogenates of vehicle or PFA1 treated male mice. There were no
significant differences in any of the cytokines assayed.
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Figure 5 TGFb and SDF1 are negatively correlated with brain Ab, while TNFa and MCP-1 are positively correlated in 22 month old
mice. A. Correlational analyses were performed between inflammatory cytokines and soluble (DEA) brain Ab1-40 levels in female mice. TGFb
and SDF1 were significantly negatively correlated with Ab1-40 levels (R2 = 0.4633, p < 0.01; R2 = 0.6421, p < 0.001, respectively). Other cytokines
were not significantly correlated with soluble Ab1-40. B. TGFb and SDF1 were also significantly correlated with soluble Ab1-42 levels (R2 =
0.4371, p < 0.01; R2 = 0.5489, p < 0.01, respectively). Other cytokines were not significantly correlated with soluble Ab1-42. C. Correlational
analyses were performed between inflammatory cytokines and total Ab1-40 levels in male mice. TNFa was significantly correlated with total (FA)
Ab1-40 levels (R2 = 0.3851, p < 0.05). Other cytokines were not significantly correlated with total Ab1-40. D. Data from female and male mice
were combined and correlational analyses performed. TNFa and MCP-1 were significantly correlated with soluble Ab1-40 levels (R2 = 0.1871, p <
0.01; R2 = 0.2466, p < 0.01, respectively). Other cytokines were not significantly correlated with soluble Ab1-40. E. MCP-1 was significantly
correlated with total Ab1-40 levels in females and males (R2 = 0.1780, p < 0.05). F. TNFa and MCP-1 were significantly correlated with soluble
Ab1-42 levels in females and males (R2 = 0.2018, p < 0.05).
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MCP-1 is decreased, and is positively correlated with
brain Ab, in immunized 17 month old female mice
PFA1 immunization significantly increased the levels of
TNFa and MCP1 in 22 month old female mice. There-
fore, we determined whether cytokine levels were altered
with immunization in the 17 month old group of female
mice. To test this, we measured brain levels of MCP-1,
IL-10, SDF-1, and RANTES in PBS-treated versus
PFA1-treated groups. The immunized female mice had
a significant 26% decrease in MCP-1 following treat-
ment (p < 0.05) (Fig. 9A).
Finally, we determined whether specific CNS cytokines
were consistently correlated with brain Ab levels, and
found that MCP-1 decreased as soluble, insoluble, and
total Ab40 in female mice decreased (R2 = 0.45,
p < 0.05; R2 = 0.615, p < 0.01, R2 = 0.764, p < 0.01,
respectively) (Fig. 9B-D). This data is consistent with
results found with the 22 month old mice.
Discussion
Here, we examined the efficacy of a passive immuniza-
tion paradigm using the monoclonal antibody PFA1 in
reducing brain Ab in a triple transgenic model of AD.
We first demonstrate that the antibody binds to both
Ab40 and Ab42 species, and binds to both oligomeric
and monomeric forms (Fig. 1). Chronic passive immuni-
zation of 22 month-old 3 × tg AD mice resulted in a
significant decrease in brain Ab accompanied by an
increase in serum Ab in male mice with intermediate
(less advanced) Ab/amyloid pathology (Fig. 2, 3). How-
ever, immunization of 22 month-old female 3 × tg AD
mice with advanced Ab pathology had no effect on
reducing brain Ab while increasing levels of inflamma-
tory cytokines TNFa and MCP-1 (Fig. 2, 3, 4). These
effects were presumably pathology burden- and not sex-
dependent, as immunization of 17 month-old female
mice with intermediate pathology resulted in trends
towards decreased brain Ab, increased clearance of Ab
to the periphery, and a decrease in the inflammatory
cytokine MCP-1 (Figs. 7, 8, 9).
We demonstrated a significant reduction in total Ab42
in immunized 22 month-old male 3 × tg AD mice.
Although effects on total Ab40 or soluble Ab40 or
Ab42 were not statistically different, all species of Ab
showed a consistent trend towards decreased Ab follow-
ing passive immunization. Similarly, 17 month-old
female 3 × tg AD mice showed consistent, but non-sig-
nificant, trends toward decreased Ab of all forms. These
results were in contrast to those observed in the 22
month-old females, where there was no evidence of
decreased Ab of any species, with a possible increase in
soluble Ab42. While our results suggest that there may
be an effect of PFA1 passive immunization on reducing
all forms of brain Ab at intermediate pathological stages,
it will be necessary to expand the size and scope of this
study due to address this issue.
The peripheral sink hypothesis of Ab clearance sug-
gests that increasing Ab-binding agents in the periphery
enhances Ab efflux from the brain [14,22]. In our stu-
dies, we observed a concurrent increase in serum Ab
with a decrease in brain Ab in 22 month-old male mice,
and a concurrent increase in serum Ab with a trend
towards decreased brain Ab in 17 month-old female
mice. Our findings support the possibility that both pas-
sive and active immunization involve antibody-mediated
clearance of Ab from the brain to the periphery. This
effect can occur independently of an antibody effect in
the brain which may incite microglial phagocytosis. Ab-
binding agents, not limited to antibodies, such as
Figure 6 PFA1 treated 22 month old male, but not female,
mice show a decreased trend in phospho-tau. A. Brain
homogenates from PFA1-treated 22 month old female mice were
Western blotted for phospho-tau (AT8, AT180) or total tau. PFA1-
treated female mice did not show any significant differences in
phospho-tau by either AT8 or AT180 normalized to total tau levels.
B. Brain homogenates from PFA1-treated 22 month old male mice
were Western blotted for phospho-tau or total tau. PFA1-treated
male mice showed a trend towards decreased phospho-tau by
AT180 normalized to total tau (66%) compared to vehicle-treated
controls.
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heparin [23] and the Nogo receptor [24], are also effec-
tive in reducing brain Ab. In addition, active immuniza-
tion of an AD mouse model lacking the FcR, which is
necessary for immune activation, still reduces brain Ab
[25], and deglycosylated antibodies, which do not bind
the FcR, increase Ab clearance to the periphery [26].
These findings suggest that peripheral clearance of Ab is
a viable mechanism by which passive or active immuni-
zation may decrease brain Ab levels.
Although passive immunization does not directly
involve T-cell activation, it can still induce microglial
activation and upregulation of inflammatory cytokines.
Indeed, we observed that the inflammatory cytokine
TNFa and chemokine MCP-1 were increased following
immunization in 22 month-old female mice in the
absence of any benefit on lowering brain Ab. TNFa is
increased in human AD brains [27] and is increased fol-
lowing antibody treatment in cultured cells [26]. MCP-1
is a chemokine which is also upregulated in serum of
AD patients and may play a role in early inflammatory
events [28]. The effects of microglial activation may be
pathology-dependent, as TNFa induction in younger
PS1xAPP mice results in microglial phagocytosis while
activation at older ages results in cytotoxic effects [29].
Thus, immune modulation at advanced pathology may
increase potentially adverse inflammatory effects of
microglial activation compared to a neuroprotective
phagocytic Ab/amyloid clearance effect found with
lower disease burden.
In addition to the increased cytokine levels following
passive immunization in mice with advanced pathology,
we also observed significant positive correlations
between increasing Ab levels and increasing TNFa and
MCP-1 levels, further supporting a pro-inflammatory
role for these cytokines. In contrast, we observed an
inverse correlation with other cytokines – as Ab levels
increased, TGFb and SDF1 decreased, implicating a ben-
eficial role for these cytokines in mediating anti-Ab
effects. This hypothesis is supported by evidence that
overexpressing TGFb in hAPP mice results in decreased
numbers of plaques [30] and reducing TGFb signaling
in mice results in increased Ab accumulation and neu-
rodegeneration [31]. Expression of the chemokine SDF1
is decreased in early AD brains [32], suggesting that dis-
regulation of its chemotactic signaling properties may
Figure 7 17 month-old PFA1-treated female mice show trends towards decreased brain Ab40 and Ab42. A. Ab1-40 levels were measured
from DEA-extracted (soluble proteins, left) and FA-extracted (insoluble, middle) brain lysates from vehicle (n = 5) or PFA1-treated (n = 5) 17
month-old female mice. Total Ab levels were calculated as the sum of soluble and insoluble Ab levels. There was a trend towards decreased
soluble (25%) and insoluble (17%) Ab1-40 levels in PFA1-treated female mice. B. Ab1-42 levels were measured from DEA and FA lysates from the
same female mice treated with vehicle or PFA1. There was a trend towards decreased soluble (32%) and insoluble (24%) Ab1-42 levels in PFA1-
treated female mice.
Figure 8 Plasma Ab is increased in 17 month-old PFA1-treated
female mice. A. Ab1-40 levels were measured from plasma
collected from vehicle and PFA1 treated 17 month-old female mice
before and after 4 weeks of treatment. There was no significant
change in plasma Ab1-40 levels following treatment in vehicle
treated animals. There was a trend towards increased Ab1-40 levels
in PFA1-treated female mice (140%) after 4 weeks of treatment. B.
Ab1-42 levels were measured from plasma collected from 17
month-old vehicle and PFA1 treated female mice before and after
treatment. There were no significant changes to Ab1-42 in vehicle-
treated animals, but a significant 34% increase (p < 0.05) in PFA1-
treated animals following treatment.
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either be an early symptom of AD or may contribute to
later AD pathology.
Conclusions
In conclusion, our study is the first to establish pathol-
ogy burden-dependent effects of passive immunization
in an animal model of AD. Treatment at an intermedi-
ate pathological stage is more effective at reducing brain
Ab, while treatment at a more advanced stage induces
neuroinflammatory effects. In addition, our findings sup-
port previous studies that passive immunization, as well
as active immunization, results in the clearance of Ab
from the brain to the periphery. High levels of Ab
pathology may contribute to neurotoxic effects mediated
by microglial inflammation, while immunomodulation at
an intermediate stage may allow the larger pool of solu-
ble Ab to be sequestered into the periphery. These find-
ings highlight the importance of considering disease
burden in determining optimal passive immune timing
and dosage in order to maximize therapeutic effects and
minimize adverse effects when considering a human
intervention.
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